Navigation Links
Allos in Medical News

Industry Veterans Rash and Rutledge Launch RegionalCare Hospital Partners to Acquire and Operate Hospitals in Non-Urban Markets

...n approximately 600 companies in 30 countries. The firm has invested more than $6.5 billion in healthcare companies, including investments in allos Therapeutics, American Medical Systems, Bausch & Lomb, Coventry Health Care, Eurand, Euromedic International (acquired by Merrill Lynch Global Pri...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes

... Corp. (Nasdaq: UTHR ) Valeant Pharmaceuticals Int'l (NYSE: VRX ) Vertex Pharmaceuticals (Nasdaq: VRTX ) Add Adolor Corp. (Nasdaq: ADLR ) allos THERAPEUTICS INC. (Nasdaq: ALTH ) Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY ) Alpharma Inc. (NYSE: ALO ) Altus Pharmaceuticals Inc. (Nasdaq:...

Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing

...iversity, Long Beach. "I am very excited to join allos and lead the Company's manufacturing activities," said Mr. Bennett. "I believe allos has the product candidates and leadership team to ...ew therapies for the treatment of cancer." About allos Therapeutics, Inc. ...

Allos Therapeutics to Present at the 2007 RBC Capital Markets Healthcare Conference

...ch will be accessible through a link posted on the allos website home page and investor relations section. ... Allos' website through December 28, 2007. About allos Therapeutics, Inc. allos Therapeutics is a biopharmaceutical company focuse...

Allos Therapeutics Reports Third Quarter 2007 Financial Results

...al 480-629-9562. Participants should reference the allos Therapeutics conference call. Conference Call Rep...llos.com and will be archived for 30 days. About allos Therapeutics, Inc. allos Therapeutics, Inc. (ALTH) is a biopharmaceutical c...

Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference

...be available for replay on Allos' website through November 20, 2007. About allos Therapeutics, Inc. allos Therapeutics is a biopharmaceutical company focused on the development and ...
Allos in Medical Technology

Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma

WESTMINSTER, Colo., Dec. 27 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH ) today announced that an independent Data Monitoring Committee (DMC) has completed the pre-specified 65-patient safety review of data from the Company's pivotal Phase 2 PROPEL trial of PDX (pralatrex...

Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma

PROPEL Enrollment Ahead of Schedule with Completion Expected Q2 2008 WESTMINSTER, Colo., Sept. 24 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH ) today announced the completion of pre-planned interim analyses of patient response and safety data from the Company's pivotal ...

William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman

...at Sofinnova Ventures and serves as Chairman of the Board of Directors at Intermune and a member of the Board of Directors of Inspire Pharmaceuticals, allos Therapeutics, Alvine Pharmaceuticals, Portola Pharmaceuticals, and BioCrossroads, a not for profit organization. Mr. Ringo holds a B.S. and an M.B.A. ...

Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma

...mphoma represents approximately 10 percent. About allos Therapeutics, Inc. allos Therapeutics, Inc. (ALTH) is a biopharmaceutical c...resentation, except as required by law. Note: The allos logo is a trademark of...

BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer

...t PARP-1 (poly-ADP-ribose polymerase), an enzyme crucial to cell repair and upregulated in certain tumors. Mr. Malek joins BiPar after seven years at allos Therapeutics where, as vice president of corporate development, he played a pivotal role in shifting Allos' strategy to focus solely on oncology asset...

Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma

...otrexate and certain other DHFR inhibitors. About allos Therapeutics, Inc. allos Therapeutics is a biopharmaceutical company focuse...resentation, except as required by law. Note: The allos logo is a trademark of...

Allos Therapeutics' PDX Granted Orphan Medicinal Product Designation by the European Commission

...irst-line or relapsed or refractory PTCLs. About allos Therapeutics, Inc. allos Therapeutics, Inc. (ALTH) is a biopharmaceutical c...pt as required by law. Note: EFAPROXYNTM and the allos logo are trademarks of Allos Therapeutics, Inc. ...

Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer

...1-689-8567. Call participants should reference the allos Therapeutics conference call. Conference Call Re...los.com and will be archived for 30 days. About allos allos Therapeutics, Inc. (ALTH) is a biopharmaceutical c...
Allos in Medical Definition

Allopathic medicine

...the symptoms. Often contrasted with homeopathy." [2] Other sources define allopathic medicine more in accord with the meaning of its word parts, allos meaning opposite and path meaning disease . Steadman's Medical Dictionary calls it a "therapeutic system in which a disease is treated by prod...
Allos in Biological Technology

OncoMed Pharmaceuticals Appoints Sunil Patel Senior Vice President, Corporate Development

...ale of that company to Sanofi-Aventis in April of this year. Previously, he held senior corporate development, marketing, and strategy positions with allos Therapeutics, Connetics Corporation, Abgenix and Gilead Sciences. Mr. Patel also served as a consultant with McKinsey & Company. Earlier in his ...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...SDAQ: ALXN ) ALKERMES INC. (NASDAQ: ALKS ) ALLERGAN INC. (NYSE: AGN ) allos THERAPEUTICS INC. (NASDAQ: ALTH ) ALNYLAM PHARMACEUTICALS INC. (NASDAQ: ...TM) Emerging Cancer Index (HHJ) Drop AETERNA ZENTARIS INC. (TSE: AEXS) allos THERAPEUTICS INC. (NASDAQ: ALTH ) ARQULE INC. (NASDAQ: ARQL ) ARRAY BIO...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes (As Revised)

...tics Corp. (Nasdaq: UTHR ) Valeant Pharmaceuticals Int'l (NYSE: VRX ) Vertex Pharmaceuticals (Nasdaq: VRTX ) Add Adolor Corp. (Nasdaq: ADLR ) allos THERAPEUTICS INC. (Nasdaq: ALTH ) Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY ) Alpharma Inc. (NYSE: ALO ) Altus Pharmaceuticals Inc. (Nasdaq: A...

Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

...e available for replay on Allos' website through February 22, 2008. About allos Therapeutics, Inc. allos Therapeutics is a biopharmaceutical company focused on the development and ...

Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus Conference

...be available for replay on Allos' website through November 27, 2007. About allos Therapeutics, Inc. allos Therapeutics is a biopharmaceutical company focused on the development and ...

Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference

...s referenced above are available for review on the allos website (http://www.allos.com ) under the "Presen...Investor Relations" section of the website. About allos Therapeutics, Inc. allos Therapeutics, Inc. (ALTH) is a biopharmaceutical c...

Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference

... be available for replay on Allos' website through October 12, 2007. About allos Therapeutics, Inc. allos Therapeutics is a biopharmaceutical company focused on the development and ...

Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference

...e available for replay on Allos' website through September 21, 2007. About allos Therapeutics, Inc. allos Therapeutics is a biopharmaceutical company focused on the development and ...
Other Tags
(Date:8/20/2014)... New York, NY (PRWEB) August 20, 2014 ... Trailblazer Awards. PM360, a leading health-marketing industry trade magazine, ... in 2009, the Trailblazer Awards are given to outstanding ... industry has to offer. , “We are proud ... to our call to entries with double the number ...
(Date:8/20/2014)... A Missouri federal judge has remanded a lawsuit filed ... GranuFlo and NaturaLyte to the City of St. Louis Circuit ... The judge rejected an assertion by the defendants that the ... et al. v. Fresenius Medical Care North America Inc., et ... the manufacturer of the dialysis products GranuFlo and NaturaLyte. In ...
(Date:8/20/2014)... "I decided that there needed to be a ... without the hassles associated with using conventional oral devices," ... DR. GATES ORAL-HYGIENE TOOL provides an easy way to ... oral hygiene and fresh breath, and it eliminates the ... eco-friendly and easy to use, the device is producible ...
(Date:8/20/2014)... Manchester and Auckland suggest that both major forms of diabetes ... findings, published today in the FASEB Journal (20 ... type-2 diabetes are both caused by the formation of toxic ... results, based on 20 years, work in New Zealand, suggest ... and potentially reversed by medicines that stop amylin forming these ...
(Date:8/20/2014)... August 20, 2014 According to ... by technology (Electrochromics, SPD, Liquid Crystal, Microblinds, Thermographic ... generation, Electronics & others), by geography - Global ... the value of Smart glass market was worth ... reach $5814 Million by 2020, at an estimated ...
Breaking Medicine News(10 mins):Health News:PM360 Announces 2014 Trailblazer Award Finalists 2Health News:PM360 Announces 2014 Trailblazer Award Finalists 3Health News:PM360 Announces 2014 Trailblazer Award Finalists 4Health News:PM360 Announces 2014 Trailblazer Award Finalists 5Health News:PM360 Announces 2014 Trailblazer Award Finalists 6Health News:PM360 Announces 2014 Trailblazer Award Finalists 7Health News:PM360 Announces 2014 Trailblazer Award Finalists 8Health News:GranuFlo/NaturaLyte Case Remanded to State Court By Missouri Federal Judge, Baron and Budd Reports 2Health News:Scientists show type-1 and type-2 diabetes are caused by same underlying mechanism 2Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 2Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 3Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 4Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 5
(Date:8/19/2014)... Long-Term Ecological Research and Network-Level Science, , Imagine if ... range of ecosystems was responding to global changes in ... if it coupled multiple decades of information about ecological ... models from dozens of different ecosystem types. , ... Ecological Research (LTER) Network, which will soon celebrate its ...
(Date:8/19/2014)... and tuberculosis live side-by-side. Worldwide there are approximately ... nearly all of them occurring where tuberculosis is ... or BCG, provides only partial protection against both ... is needed to combat both diseases. UCLA-led research ... diseases., In a study published in the September ...
(Date:8/19/2014)... engineers have devised a new implantable tissue scaffold coated ... a few weeks. When applied to bone injuries or ... form new bone that looks and behaves just like ... could offer a dramatic improvement over the current standard ... another part of the patient,s body a painful ...
Breaking Biology News(10 mins):This week from AGU: Long-term ecological research, predicting cholera outbreaks 2New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Engineering new bone growth 2Engineering new bone growth 3
Other Contents